Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01913327 · ClinicalTrials.gov registry record · Phase 4
Antipsychotic Effects on Brain Function in Schizophrenia
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT01913327 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 4 participants.
The verdict
NCT01913327, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.
Interventions
- DRUG Risperidone
- DRUG Modafinil
- DRUG Aripiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01913327
The ClinicalTrials.gov registry entry for NCT01913327 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Risperidone is the first listed.
NCT01913327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01913327 about?
NCT01913327 is a clinical study titled "Antipsychotic Effects on Brain Function in Schizophrenia". The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophrenia patients.
What is the current status of trial NCT01913327?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2013-04. Estimated completion is 2017-01.
What interventions are being tested in trial NCT01913327?
The interventions under investigation include: Risperidone (DRUG), Modafinil (DRUG), Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT01913327?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.